Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Dise...
March 24 2015 - 8:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced the
company has signed an agreement with Novo Nordisk under which
Bristol-Myers Squibb will acquire an exclusive global license to a
discovery biologics research program focused on modulating the
innate immune system as a therapy for autoimmune diseases. Terms of
the agreement were not disclosed.
The agreement supports Bristol-Myers Squibb’s long-standing
commitment to immunoscience, a core therapeutic area with multiple
innovative drug candidates in development to target immune-mediated
diseases with high unmet medical needs.
The innate immune system is the body’s first line of defense
against pathogens and responds to exogenous agents in an antigen
non-specific way to stimulate an immediate protective response.
Dysregulated innate immunity plays a critical role in the induction
and pathogenesis of autoimmune diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorSarah Koenig,
609-252-4145sarah.koenig@bms.comorInvestors:Ranya Dajani,
609-252-5330ranya.dajani@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024